Skip to main content
SpringerLink
Log in

Streptogramins and their Potential Role in Geriatric Medicine

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Despite advances in antimicrobial chemotherapy over recent decades, morbidity and mortality secondary to infection continues to rise. In addition, the incidence of infection caused by resistant organisms has also increased. Concurrently, the elderly are living longer than prior generations, often with disabling chronic diseases. The more debilitated of the geriatric population are at greater risk for infection, and more likely to acquire or develop antimicrobial resistant organisms. Gram-positive organisms are a source of resistance and commonly cause infection in older patients. Whereas resistance is a concern in all patients, in the elderly this is magnified by limitations in treatment options because of differences in pharmacokinetics and tolerance as compared with younger counterparts. Pharmacokinetic differences include changes in drug distribution and may arise as a result of diminished end organ function. Age-related decreases in renal function often impact on commonly prescribed antimicrobials. In addition, the elderly are more susceptible to drug-drug interactions because polypharmacy is common in this patient population.

Streptogramins may offer a useful alternative in the treatment of infections in the elderly due to their coverage of organisms commonly causing infections in this population and because of their favourable pharmacokinetic profiles. While published experience is limited, streptogramins are not appreciably eliminated by the kidney and, therefore, they are less subject to age-related changes in renal elimination. What is required is multi-dose pharmacokinetic analysis of streptogramins in geriatric populations and subset analysis of patient use data on file.

The following will provide the reader with the most recently presented data on streptogramin use and their potential. While focusing on potential use in the elderly, we have cited data and issues which we believe will be relevant in the geriatric population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997; 39 Suppl. A: 1–6

    Article  PubMed  CAS  Google Scholar 

  2. Appelbaum PC. Emerging resistance to antimicrobial agents in gram-positive bacteria: pneumococci. Drugs 1996; 51 Suppl. 1: 1–5

    Article  PubMed  CAS  Google Scholar 

  3. Bouanchaud DH. In vitro and in vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother 1997; 39:Suppl. A: 15–21

    Article  PubMed  CAS  Google Scholar 

  4. Rubinstein E, Keller N. Future prospects and therapeutic potential of streptogramins. Drugs 1996; 51 Suppl. 1: 38–45

    Article  PubMed  CAS  Google Scholar 

  5. Turco TF, Melko GP, Williams JR. Vancomycin intermediate-resistant staphylococcus aureus. Ann Pharmacother 1998; 32: 758–60

    Article  PubMed  CAS  Google Scholar 

  6. Bryson HM, Spencer CM. Quinupristin-Dalfopristin. Drugs 1996; 52: 406–15

    Article  PubMed  CAS  Google Scholar 

  7. Williams JD, Maskell JP, Whiley AC, et al. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. J Antimicrob Chemother 1997; 39 Suppl. A: 41–6

    Article  PubMed  CAS  Google Scholar 

  8. Johnson AP, Warner M, Speller DCE. In-vitro activity of quinupristin/dalfopristin (Synercid) against isolates of Streptococcus pneumoniae, staphylococcus aureus and Enterococcus spp. J Antimicrob Chemother 1997; 40: 604–5

    Article  PubMed  CAS  Google Scholar 

  9. Yoshikawa TT, Norman DC. Approach to fever and infection in the nursing home. J Am Geriatr Soc 1996; 44: 74–82

    PubMed  CAS  Google Scholar 

  10. Ruben FL, Dearwater SR, Norden, et al. Clinical infections in the non institutionalized geriatric age group: methods utilized and incidence of infections. Am J Epidemiol 1995; 141: 145–57

    PubMed  CAS  Google Scholar 

  11. Cahill CK, Rosenberg J. Guidelines for prevention and control of antibiotic-resistant microorganisms. J Gerontol Nurs 1996; 22: 40–7

    PubMed  CAS  Google Scholar 

  12. Crossley KB, Peterson PK. Infections in the elderly. Clin Infect Dis 1996; 22: 209–15

    Article  PubMed  CAS  Google Scholar 

  13. Hebert R. Functional decline in old age. Can Med Assoc J 1997; 157: 1037–45

    CAS  Google Scholar 

  14. Nicolle LE, Bentley D, Garibaldi R, et al. Antimicrobial use in long-term-care facilities. Infect Control Hosp Epidemiol 1996: 17: 119–28

    Article  PubMed  CAS  Google Scholar 

  15. Lewis DA, Reeves DS. Antibiotics at the extremes of age: choices and constraints. J Antimicrob Chemother 1994; Suppl. A: 11–8

    Google Scholar 

  16. Das SS, Anderson JR, Macdonald AA, et al. Endocarditis due to high level gentamicin resistant Enterococcus faecium. J Infect 1995; 28: 185–91

    Article  Google Scholar 

  17. Boswell FJ, Sunderland J, Andrews JM, et al. Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods. J Antimicrob Chemother 1997; 39 Suppl. A: 29–32

    Article  PubMed  CAS  Google Scholar 

  18. Hill RLR, Smith CT, Seyed-Akhavani M, et al. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium. J Antimicrob Chemother 1997; 1997; 39 Suppl. A: 23–8

    Article  CAS  Google Scholar 

  19. Chant C, Rybak MJ. Quinupristin/dalfopristin (RP59500): a new streptogramin antibiotic. Ann Pharmacother 1995; 29: 1022–7

    PubMed  CAS  Google Scholar 

  20. Griswold MW, Lomaestro BM, Briceland LL. Quinupristin-dalfopristin (RP59500): an injectable streptogramin combination. Am J Health Syst Pharm 1996; 53: 2045–53

    PubMed  CAS  Google Scholar 

  21. Low DE. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Mirobiol Drug Resist 1995; 1: 223–34

    Article  CAS  Google Scholar 

  22. Pechere JC. Streptogramins: a unique class of antibiotics. Drugs 1996; 51 Suppl. 1: 13–9

    Article  PubMed  CAS  Google Scholar 

  23. Cocito C, Giambattista Di M, Nyssen E, et al. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimcirob Chemother 1997; 39 Suppl. A: 7–13

    Article  CAS  Google Scholar 

  24. Jamjian C, Barrett MS, Jones RN. Antimicrobial characteristics of quinupristin/dalfopristin (synercid at 30:70 ratio) compared to alternative ratios for in vitro testing. Diagn Microbiol Infect Dis 1997; 27: 129–38

    Article  PubMed  CAS  Google Scholar 

  25. Carbon C. Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection. J Antimicrob Chemother 1997; 39 Suppl. A: 115–9

    Article  PubMed  CAS  Google Scholar 

  26. Barry AL, Fuchs PC, Brown SD. In. vitro activity of an orally administered streptogramin (RPR 106972) compared to quinupristin/dalfopristin and erythromycin. Eur J Clin Microbiol Infect Dis 1997; 16: 155–8

    Article  PubMed  CAS  Google Scholar 

  27. Pendland SL, Killian AD, Woodward JG, et al. In-vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with rifampicin or ciprofloxacin against Legionella spp. J Antimicrob Chemother 1997; 39: 651–3

    Article  PubMed  CAS  Google Scholar 

  28. Spangler SK, Jacobs MR, Appelbaum PC. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996; 40: 481–4

    PubMed  CAS  Google Scholar 

  29. Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides. Drugs 1996; 51 Suppl. 1: 20–30

    Article  PubMed  CAS  Google Scholar 

  30. Rubinstein E, Bompart F. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. J Antimcirob Chemother 1997; 39 Suppl. A: 139–43

    Article  CAS  Google Scholar 

  31. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet 1997; 33: 302–12

    Article  PubMed  CAS  Google Scholar 

  32. Swift CG. Pharmacokinetics and prescribing in the elderly. J Antimicrob Chemother 1994; 34 Suppl. A: 25–32

    Article  PubMed  Google Scholar 

  33. Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimcirob Chemother 1997; 39 Suppl. A: 129–38

    Article  CAS  Google Scholar 

  34. Barry AL, Fuchs PC, Brown SD. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother 1997; 39 Suppl. A: 87–92

    Article  PubMed  CAS  Google Scholar 

  35. Lefebvre P, Rey J, Morganroth J, et al. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin in obese and in non-obese male subjects [abstract 2308]. 20th International Congress of Chemotherapy; 1997 June 29–July 3, Sydney

  36. Bergeron MG, Trottier S, Lepage MC, et al. A phase I, open-label study of blood and blister fluid pharmacokinetics of quinupristin/dalfopristin [abstract A-117]. 37th International Congress of Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

  37. Lefebvre P, Geary B, Rey J, et al. Open comparative study of the pharmacokinetic and safety of a single dose of quinupristin/dalfopristin in healthy male and female volunteers [abstract 2306]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney

  38. Chevalier P, Rey J, Boucher E, et al. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin in subjects with hepatic cirrhosis and healthy volunteers [abstract 2307]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney

  39. Chevalier P, Rey J, Franke H, et al. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin in patients with severe chronic renal failure and in healthy volunteers [abstract 2309]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney

  40. Burucoa C, Pasdeloup T, Chapon C, et al. Failure of pristinamycin treatment in a case of pneumococcal pneumonia. Eur J Clin Infect Dis 1995; 14: 341–2

    Article  CAS  Google Scholar 

  41. Lefebvre P, Rey J, Harding N, et al. Open, comparative study of the pharmacokinetic and safety of a single dose of quinupristin/dalfopristin in healthy elderly volunteers and healthy young volunteers [abstract 2311]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  42. Chevalier P, Rey J, Rouzier-Panis R, et al. Multiple-dose pharmacokinetics and safety of quinupristin/dalfopristin in healthy volunteers [abstract 2310]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  43. Data on file, Rhone Poulenc-Rorer Pharmaceuticals Inc., 500 Arcola Road Collegeville, PA 19426, USA, and Antony, France 1998

  44. Bompart F, Dorr M, Bekele T, et al. Overview of the safety and tolerability of quinupristin/dalfopristin in the global development program [abstract 2318]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  45. Moellerinig RC, Linden PK, Quinupristin/dalfopristin Emergency-Use Study Group. Efficacy and safety of quinupristin/dalfopristin in the treatment of vancomycin-resistant Enterococcus faecium infections [abstract 2320]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  46. McCue JD. Antibiotic resistance: why is it increasing in nursing homes? Geriatrics 1997; 52: 34–43

    PubMed  CAS  Google Scholar 

  47. Strausbaugh LJ, Crossley KB, Nurse BA, et al. Antimicrobial resistance in long-term-care facilities. Infect Control Hosp Epidemiol 1996; 17: 129–40

    Article  PubMed  CAS  Google Scholar 

  48. Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Suppl. A: 53–8

    Article  PubMed  CAS  Google Scholar 

  49. Loncle V, Casetta A, Buu-Hoi A, et al. Analysis of pristinamycin-resistant Staphylococcus epidermidis isolates responsible for an outbreak in a Parisian hospital. Antimicrob Agents Chemother 1993; 37: 2159–65

    Article  PubMed  CAS  Google Scholar 

  50. Kang SL, Rybak MJ. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39 Suppl. A: 33–9

    Article  PubMed  CAS  Google Scholar 

  51. Lorian V, Fernandes F. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium. J Antimicrob Chemother 1997; 39 Suppl. A: 63–6

    Article  PubMed  CAS  Google Scholar 

  52. Vouillamoz J, Entenza JM, Giddey M, et al. Quinupristin/dalfopristin alone or combined to cefamandole in the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) constitutively resistant to erythromycin [abstract B-27]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  53. Finch RG. Antibacterial activity of quinupristin/dalfopristin: rationale for clinical use. Drugs 1996; 51 Suppl. 1: 31–7

    Article  PubMed  CAS  Google Scholar 

  54. Tenover FC, Baker CN. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin. J Antimcirob Chemother 1997; 39 Suppl. A: 81–5

    Article  CAS  Google Scholar 

  55. Jones RN, Ballow CH, Biedenbach D, et al. Streptogramin combination (quinupristin/dalfopristin) activity and spectrum from a 1997 study in over 200 medical centers: analysis for regional variations, co-resistance and validity of proposed susceptible breakpoints [abstract E-134]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  56. Pankuch GA, Lichtenberger C, Jacobs MR, et al. Anti-pneumococcal activities of RP59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies. Antimicrob Agents Chemother 1996; 40: 1653–6

    PubMed  CAS  Google Scholar 

  57. Tarasi A, Dever LL, Tomasz A. Activity of quinupristin/dalfopristin against Streptococcus pneumoniae in vitro and in vivo in the rabbit model of experimental meningitis. J Antimicrob Chemother 1997; 39 Suppl. A: 121–7

    Article  PubMed  CAS  Google Scholar 

  58. Barry AL, Brown SD, Fuchs PC. Antipneumococcal activity of a ketolide (HMR 3647) and seven related drugs in vitro [abstract F-107]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  59. Pankuch GA, Jacobs MR, Appelbaum PC. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 1996; 40: 2071–4

    PubMed  CAS  Google Scholar 

  60. Koechlin C, Kempf JF, Jehl F, et al. Single oral dose pharmacokinetics of the two main components of pristinamycin in humans. J Antimicrob Chemother 1990; 25: 651–6

    Article  PubMed  CAS  Google Scholar 

  61. De Azavedo JC, Trpeski L, Pong-Porter, et al. In vitro activity of new drugs against multi-drug resistant streptococci of the viridans group collected from across Canada [abstract E 54]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  62. Tuohy M, Washington JA. Antimicrobial susceptibility of viridans group streptococci [abstract E-113]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  63. Herrera-Insua I, Jacques-Palz K, Murray BE, et al. Intracellular activities of RP5900 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Antimicrob Agents Chemother 1996; 40: 886–90

    PubMed  CAS  Google Scholar 

  64. Herrera-Insua I, Jacques-Palaz K, Murray BE, et al. The effect of antibiotic exposure on adherence to neutrophils of Enterococcus faecium resistant to phagocytosis. J Antimicrob Chemother 1997; 39 Suppl. A: 109–13

    Article  PubMed  CAS  Google Scholar 

  65. Messick CR, Pendland SL. In vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with vancomycin and gentamicin against vancomycin-resistant Enterococcus faecium [abstract E-137]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  66. Carbon F, Gold HS, Wennersten CB, et al. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997; 41: 2749–53

    Google Scholar 

  67. Chow JW, Davidson A, Sanford E, et al. Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1996; 24: 91–2

    Article  Google Scholar 

  68. Chow JW, Donabedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium. Clin Infect Dis 1997; 24: 90–1

    Article  PubMed  CAS  Google Scholar 

  69. Piper J, Furness K, Steele-Moore L, et al. Quinupristin/dalfopristin (Synercid) resistant vancomycin resistant Enterococcus faecium [abstract C-80]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  70. Struwig MC, Botha PL, Chalkley LJ. Investigation of the antibacterial activity of BAY 12-8039 against South African isolates of enterococci [abstract F-138]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 September 28–October 1; Toronto

  71. Hamilton-Miller JMT, Shah S. Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. J Antimicrob Chemother 1997; 39 Suppl. A: 103–8

    Article  PubMed  CAS  Google Scholar 

  72. Robinson-Dunn B, Jennings G, Mitchell J, et al. Characterization of a unique isolate of vancomycin-intermediate Staphylococcus aureus (VISA) [abstract LB-14]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  73. Jorgensen JH, McElmeel ML. Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae. J Antimicrob Chemother 1997; 39 Suppl. A: 69–73

    Article  PubMed  CAS  Google Scholar 

  74. Lube MM, Botha PL, Chalkley LJ. Comparative activities of sixteen antimicrobial agents against anaerobic bacteria isolated in South Africa [abstract E-171]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  75. Fainelli B, Magi G, Prenna M, et al. In vitro extracellular and intracellular activity of two newer and two earlier fluoroquinolones against Listeria monocytogenes. Eur J Clin Microbiol Infect Dis 1997; 16: 827–33

    Article  Google Scholar 

  76. Steele Moore L, Schneider B, Holloway WJ. Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes. J Antimicrob Chemother 1997; 39 Suppl. A: 67–8

    Article  Google Scholar 

  77. Bebear C, Bouanchaud DH. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas. J Antimicrob Chemother 1997; 39 Suppl. A: 59–62

    Article  PubMed  CAS  Google Scholar 

  78. Schulin T, Wennerstein CB, Ferraro MJ, et al. Susceptibility of Legionella spp. to ketolide HMR 3647 and other newer antimicrobials [abstract F-250]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  79. Ridgway GL, Salman H, Dencer C, et al. The in-vitro activity of Quinupristin/dalfopristin (RP59500) against Chlamydia spp. Mycoplasma spp. and Ureaplasma urealyticum [abstract E-158]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  80. Aeschlimann JR, Rebuck J, Rybak MJ. Pharmacodynamic analysis of quinupristin/dalfopristin versus vancomycin-resistant Enterococcus faecium with differing MBCs using time kill curve and post-antibiotic effect methods [abstract E-136]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  81. Boellering RC. What therapeutic options do we have? [abstract S-145]. 37th International Congress of Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto

  82. Nygaard IE, Johnson JM. Urinary tract infections in elderly women. Am Fam Physician 1996; 53: 175–82

    PubMed  CAS  Google Scholar 

  83. Dever LL, Smith SM, Dejesus D, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases. Microbial Drug Resist 1996; 2: 407–13

    Article  CAS  Google Scholar 

  84. Janssens JP, Gauthey L, Herrmann F, et al. Community-acquired pneumonia in older patients. J Am Geriatr Soc 1996; 44: 539–44

    PubMed  CAS  Google Scholar 

  85. Fein AM. Pneumonia in the elderly: special diagnostic and therapeutic considerations. Med Clin North Am 1994; 78: 1015–33

    PubMed  CAS  Google Scholar 

  86. Troy CJ, Peeling RW, Ellis AG, et al. Chylamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 1997; 277: 1214–8

    Article  PubMed  CAS  Google Scholar 

  87. Baughman R. The US Quinupristin/dalfopristin CAP Study Group. Randomized, double-blind, comparative, multicenter study of quinupristin/dalfopristin versus combination of ceftriaxone and erythromycin in the treatment of acute community-acquired bacterial pneumonia [abstract 2321]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  88. Fagon JY. Global Quinupristin/dalfopristin NP Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin plus aztreonam versus vancomycin plus aztreonam in the treatment of gram-positive nosocomial pneumonia [abstract 2315]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  89. Leistevuo T, Isoaho R, Klauka T, et al. Prescription of antimicrobial agents to elderly people in relation to the type of infection. Age Aging 1997; 26: 345–51

    Article  CAS  Google Scholar 

  90. Nichols R. US Quinupristin/dalfopristin SSSI Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin versus standard therapy (oxacillin or vancomycin) in the treatment of complicated gram-positive skin and skin structure infections [abstract 2314]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  91. Beal J, Global Quinupristin/dalfopristin SSSI Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin versus standard therapy (cefazolin or vancomycin) in the treatment of complicated gram-positive skin and skin structure infections [abstract 2316]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  92. Chassagne P, Perol MB, Doucet J, et al. Is presentation of bacteremia in the elderly the same as in younger patients? Am J Med 1996; 100: 65–70

    Article  PubMed  CAS  Google Scholar 

  93. Raad I. The global quinupristin/dalfopristin DRGPB study group: dose-ranging, randomized, multicenter open phase II study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related, gram-positive bacteremia [abstract 2319]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  94. Berthaud N, Desnottes JF. In-vitro bacterial activity of quinupristin/dalfopristin against adherent Staphylococcus aureus. J Antimcirob Chemother 1997; 39 Suppl. A: 99–102

    Article  CAS  Google Scholar 

  95. Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microbial Drug Resist 1995; 1: 95–6

    Article  CAS  Google Scholar 

  96. Sahgal VS, Urban C, Mariano N, et al. Quinupristin/dalfopristin (RP59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report. Microbial Drug Resist 1995; 1: 245–7

    Article  CAS  Google Scholar 

  97. Wernber GS, Schulz R, Fuchs JB, et al. Infective endocarditis in the elderly in the era of transesophageal echocardiography: clinical features and prognosis compared with younger patients. Am J Med 1996; 100: 90–7

    Article  Google Scholar 

  98. Mouton JW, Endtz HP, den Hollander JG, et al. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J Antimicrob Chemother 1997; 39 Suppl. A: 75–80

    Article  PubMed  CAS  Google Scholar 

  99. Berthaud N, Huet Y, Diallo N, et al. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis. J Antimcirob Chemother 1997; 39 Suppl. A: 93–8

    Article  CAS  Google Scholar 

  100. Furlong WB, Rakowski TA. Therapy with RP 59500 (Quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with Van A/Van B resistance patterns. Clin Infect Dis 1997; 25: 162–3

    Article  Google Scholar 

  101. Miller LG, Choi C. Meningitis in older patients: how to diagnose and treat a deadly infection. Geriatrics 1997; 52: 43–55

    PubMed  CAS  Google Scholar 

  102. Bradley JS, Scheid WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990’s. Clin Infect Dis 1997; 24 Suppl. 2: S213–21

    Article  PubMed  CAS  Google Scholar 

  103. Ballow C, Chevalier P, Forrest A, et al. Randomized, crossover phase I study of the interaction between quinupristin/dalfopristin at steady state and cyclosporine in healthy volunteers [abstract 2312]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney

  104. Shlaes DM, Gerding DN, John Jr JF, et al. Society for healthcare epidemiology of America and infectious diseases society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584–99

    Article  PubMed  CAS  Google Scholar 

  105. Niederman MS. Introduction: COPD — the role of infection. Chest 1997; 112: Suppl.: 301–2S

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Albany Medical Center Hospital (A-85), New Scotland Ave, Albany, New York, 12208, USA

    Ben M. Lomaestro

  2. Albany College of Pharmacy, New Scotland Avenue, Albany, New York, USA

    Laurie L. Briceland

Authors
  1. Ben M. Lomaestro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurie L. Briceland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ben M. Lomaestro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lomaestro, B.M., Briceland, L.L. Streptogramins and their Potential Role in Geriatric Medicine. Drugs & Aging 13, 443–465 (1998). https://doi.org/10.2165/00002512-199813060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199813060-00004

Keywords

Search

Navigation